These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Olaparib for the treatment of breast cancer. Griguolo G; Dieci MV; Guarneri V; Conte P Expert Rev Anticancer Ther; 2018 Jun; 18(6):519-530. PubMed ID: 29582690 [TBL] [Abstract][Full Text] [Related]
23. PARP inhibitors: its role in treatment of cancer. Chen A Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592 [TBL] [Abstract][Full Text] [Related]
24. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467 [TBL] [Abstract][Full Text] [Related]
25. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331 [TBL] [Abstract][Full Text] [Related]
30. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells. Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734 [TBL] [Abstract][Full Text] [Related]
31. Olaparib Keeps Hereditary Breast Tumors in Check. Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909 [TBL] [Abstract][Full Text] [Related]
32. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. Mendes-Pereira AM; Martin SA; Brough R; McCarthy A; Taylor JR; Kim JS; Waldman T; Lord CJ; Ashworth A EMBO Mol Med; 2009 Sep; 1(6-7):315-22. PubMed ID: 20049735 [TBL] [Abstract][Full Text] [Related]
37. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088 [TBL] [Abstract][Full Text] [Related]
38. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Helleday T Mol Oncol; 2011 Aug; 5(4):387-93. PubMed ID: 21821475 [TBL] [Abstract][Full Text] [Related]
39. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Pessetto ZY; Yan Y; Bessho T; Natarajan A Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176 [TBL] [Abstract][Full Text] [Related]
40. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Clark CC; Weitzel JN; O'Connor TR Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]